This paper is in the following e-collection/theme issue:

Development of Instruments and Surveys (86) Participatory Research Protocols and Proposals (142)

Published on in Vol 12 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/43091, first published .
Evaluation of the Care Pathway in the Context of the Dispensing of Emicizumab (Hemlibra) in Community Pharmacies in France: Protocol for a Cross-sectional Study Based on the Kirkpatrick Model

Evaluation of the Care Pathway in the Context of the Dispensing of Emicizumab (Hemlibra) in Community Pharmacies in France: Protocol for a Cross-sectional Study Based on the Kirkpatrick Model

Evaluation of the Care Pathway in the Context of the Dispensing of Emicizumab (Hemlibra) in Community Pharmacies in France: Protocol for a Cross-sectional Study Based on the Kirkpatrick Model

Authors of this article:

Laurie Fraticelli1 Author Orcid Image ;   Julie Freyssenge2 Author Orcid Image ;   Emilie Promé-Combel3 Author Orcid Image ;   Eléonore Agnellet4 Author Orcid Image ;   Yesim Dargaud3 Author Orcid Image ;   Valérie Chamouard3, 4 Author Orcid Image
Article Authors Cited by (3) Tweetations (2) Metrics

Laurie Fraticelli   1 , PhD ;   Julie Freyssenge   2 , PhD ;   Emilie Promé-Combel   3 , MSc ;   Eléonore Agnellet   4 , BA ;   Yesim Dargaud   3 , MD, PhD ;   Valérie Chamouard   3, 4 , PharmD

1 Laboratory P2S (Health Systemic Process), UR 4129, University Claude Bernard Lyon 1, University of Lyon, Lyon, France

2 Research on Healthcare Performance RESHAPE, INSERM U1290, University Claude Bernard Lyon 1, University of Lyon, Lyon, France

3 French Reference Center of Hemophilia and Rare Inherited Bleeding Disorder, Louis Pradel Hospital, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France

4 Pharmaceutical Unit, Louis Pradel Hospital, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France

Corresponding Author: